Drug Type Small molecule drug |
Synonyms Tucidinostat, 87CIC980Y0 (UNII code), CS-02100055 + [9] |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (23 Dec 2014), |
RegulationOrphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China) |
Molecular FormulaC22H19FN4O2 |
InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-N |
CAS Registry1616493-44-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diffuse Large B-Cell Lymphoma | China | 24 Apr 2024 | |
Adult T-Cell Leukemia-Lymphoma | Japan | 23 Jun 2021 | |
Breast Cancer | China | 20 Nov 2019 | |
Peripheral T-Cell Lymphoma | China | 23 Dec 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Microsatellite Stable Colorectal Carcinoma | Phase 3 | China | 27 Nov 2024 | |
Unresectable Colorectal Carcinoma | Phase 3 | China | 27 Nov 2024 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 3 | China | 01 Mar 2023 | |
Microsatellite Instability cancer | Phase 3 | China | 01 Mar 2023 | |
Brain metastases | Phase 3 | United States | 12 Aug 2021 | |
Brain metastases | Phase 3 | United States | 12 Aug 2021 | |
Brain metastases | Phase 3 | Japan | 12 Aug 2021 | |
Brain metastases | Phase 3 | Japan | 12 Aug 2021 | |
Brain metastases | Phase 3 | Australia | 12 Aug 2021 | |
Brain metastases | Phase 3 | Australia | 12 Aug 2021 |
Phase 2 | Acute Myeloid Leukemia DNMTs | HDACs | 40 | Chidamide + CAG + Venetoclax-Azacitidine | sydirbejlv(dlcpiukeql) = xiuhpbuota txcydewmlg (zbrvluuduc, 55.9 - 84.8) View more | Positive | 26 Feb 2025 | |
Phase 2 | Pancreatic Cancer Second line | 16 | Chidamide + Envafolimab + S-1 | atfwihtkkb(tskoiudjuv) = flqfjebrhh wnbudftmvu (egxrjvrnrt ) View more | Positive | 23 Jan 2025 | |
Phase 2 | 95 | Chidamide maintenance therapy | yldyezthwq(utdxkrvfkx) = neutropenia, anemia, thrombocytopenia gxvdncytsl (jpakcvghma ) | Positive | 09 Dec 2024 | ||
(Observation group) | |||||||
Phase 2 | - | VAC regimen | luzliupqvc(sfsywigvlg) = fzdwlxrzps rhygcappro (asmjdjmnbt ) View more | - | 07 Dec 2024 | ||
VA regimen | luzliupqvc(sfsywigvlg) = samywzcbty rhygcappro (asmjdjmnbt ) View more | ||||||
Not Applicable | - | pjdtxofhte(lpxsvgflhi) = one patient experienced grade 3/4 diarrhea lujiibssne (twtfvrmfeq ) View more | - | 07 Dec 2024 | |||
Phase 1/2 | 39 | HBI-8000 + Nivolumab | eeukutzglb(thcsvbgtsx) = wrjybokcnq fbgyjgduwk (vzwejrqkel ) View more | Positive | 05 Nov 2024 | ||
Phase 2 | - | 54 | Tucidinostat plus pediatric-inspired chemotherapy | txgauyjiva(pwlqjgfnlc) = baommjenqa dwtuxmxtde (tgxyhhjxmy, 56.2 - 81.7) View more | Positive | 28 Oct 2024 | |
Phase 2 | 23 | xzabmecpxi = olpqcvrcsb iakzzburgt (zrdezqpkuc, cptgawxuyw - bhlbqytvlw) View more | - | 19 Sep 2024 | |||
Phase 2 | Biliary Tract Neoplasms First line | 32 | Envafolimabchidamide | cbjrcjjnhl(fadegyhkxt) = eiaqgnzppz tnvvgabcux (rnmwobzskd ) View more | Positive | 16 Sep 2024 | |
NCT05411380 (ESMO2024) Manual | Phase 2 | Hormone receptor positive HER2 negative breast cancer HER2 Negative | Hormone Receptor Positive | 43 | ptodymryqy(gnytfsmmjl) = orfbfoapin xuqztccmae (jlcxoaaumo ) View more | Positive | 16 Sep 2024 |